PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update

PolyPid Ltd. (NASDAQ:PYPD) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 9,200 shares, a growth of 33.3% from the February 13th total of 6,900 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 29,000 shares, the short-interest ratio is presently 0.3 days.

PolyPid Stock Performance

Shares of PYPD stock traded up $0.05 during mid-day trading on Monday, reaching $3.03. The stock had a trading volume of 18,830 shares, compared to its average volume of 13,279. The business’s fifty day moving average is $3.02 and its 200-day moving average is $3.23. The firm has a market cap of $30.83 million, a price-to-earnings ratio of -0.62 and a beta of 1.27. PolyPid has a 1-year low of $2.37 and a 1-year high of $5.50. The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.08.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). On average, research analysts forecast that PolyPid will post -1.79 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. RODMAN&RENSHAW raised shares of PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw began coverage on PolyPid in a research note on Tuesday, January 28th. They set a “buy” rating and a $13.00 target price on the stock. Finally, HC Wainwright decreased their price target on PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, December 26th.

Institutional Trading of PolyPid

Several institutional investors have recently bought and sold shares of PYPD. J. Goldman & Co LP purchased a new position in PolyPid during the fourth quarter valued at $391,000. Rosalind Advisors Inc. raised its holdings in shares of PolyPid by 49.9% during the fourth quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock valued at $3,095,000 after acquiring an additional 338,853 shares during the last quarter. AIGH Capital Management LLC boosted its stake in shares of PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock worth $2,509,000 after acquiring an additional 148,199 shares during the last quarter. Finally, Stonepine Capital Management LLC acquired a new stake in shares of PolyPid in the third quarter worth approximately $476,000. 26.47% of the stock is owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.